Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
Spot Ethereum ETF issuers post fee and seed investment disclosures in latest wave of amended filings
Spot Ethereum ETF issuers post fee and seed investment disclosures in latest wave of amended filings

Quick Take BlackRock, VanEck, Franklin Templeton, Grayscale Investments and 21Shares filed those amended statements on Friday. Bitwise and Fidelity filed earlier. VanEck set its fee at 0.20% after Franklin Templeton set theirs last month at 0.19%. Other issuers have not yet posted fees.

The Block·2024/06/21 21:49
Fantom introduces $120M fund to drive development on Sonic blockchain
Fantom introduces $120M fund to drive development on Sonic blockchain

Share link:In this post: Fantom Foundation has allocated 200 million FTM tokens, worth $120 million, to the Sonic Labs Innovators Fund. The foundation wants to use the fund to incentivize developers to build on the yet-to-be launched Sonic Network. Community grants is becoming a common trend among blockchain projects looking to attract developers to their ecosystem.Disclaimer. The information provided is not trading advice. Cryptopolitan.com holds no liability for any investments made based on the informat

Cryptopolitan·2024/06/21 19:40
Spot Ethereum ETFs to launch July 2nd, says Bloomberg analyst
Spot Ethereum ETFs to launch July 2nd, says Bloomberg analyst

Share link:In this post: Spot Ethereum ETFs are set to launch on July 2nd, pending final SEC approval. Bloomberg analyst Eric Balchunas confirms multiple amended ETH ETF filings expected today.Disclaimer. The information provided is not trading advice. Cryptopolitan.com holds no liability for any investments made based on the information provided on this page. We strongly recommend independent research and/or consultation with a qualified professional before making any investment decisions.

Cryptopolitan·2024/06/21 19:40
Flash
21:41
The yield on the two-year US Treasury bond has fallen by about 3 basis points.
The yield on the 2-year US Treasury fell by 2.70 basis points to 4.1101%, remaining in a downward trend throughout the day, trading within the range of 4.1350%-4.1018%. The yield on the 30-year US Treasury fell by 0.10 basis points to 4.9844%. The spread between the 2-year and 10-year US Treasury yields widened by 1.103 basis points to +35.506 basis points. The yield on the 10-year Treasury Inflation-Protected Securities (TIPS) dropped by 2.41 basis points to 2.2161%; the 2-year TIPS yield decreased by 3.05 basis points to 2.1295%; the 30-year TIPS yield declined by 0.37 basis points to 2.7962%.
21:33
Cloudastructure Inc (CSAI) recently announced that it has successfully eliminated the variable convertible feature from its debt, a move that has significantly strengthened the company's balance sheet structure.
At the same time, the company provided an update on the progress of its financial reporting for the first quarter of 2026. By removing the variable conversion clause from its debt instruments, Cloudastructure has effectively reduced the risk of future equity dilution and improved the stability of its financial structure. This adjustment is expected to give the company greater financial flexibility to support its long-term strategic development. In addition, regarding financial reporting for the first quarter of 2026, the company confirmed that relevant preparations are progressing as planned and that it will ensure the timely disclosure of complete financial information to the market. This move further demonstrates Cloudastructure's commitment to transparency and compliance.
21:33
According to a document filed with the U.S. Securities and Exchange Commission (SEC), if the transaction between Crinetics Pharmaceuticals Inc. and Vertex Pharmaceuticals is terminated under certain circumstances, the former may be required to pay the latter a termination fee of up to $350.47 million.
The document clarifies the specific circumstances that would trigger this substantial financial obligation. The terms of the agreement show that payment of this fee does not take effect automatically and is closely tied to specific termination conditions. This provides market participants and investors with key details about the financial arrangements behind this potential collaboration.Analysts point out that termination fee clauses of such a large amount are typically intended to safeguard the significant interests of both parties, especially in major strategic partnerships or acquisition negotiations. They not only demonstrate the seriousness and depth of commitment to the deal, but may also reflect the high value and expectations both sides place on its ultimate completion. However, this also means that if the agreement falls through under the stipulated conditions, Crinetics Pharmaceuticals would face significant financial outlays.Currently, the market is closely watching the latest developments from both companies and the specific progress of the deal. The disclosure of such financial arrangement details helps investors more comprehensively assess the risks and potential impacts of the related transaction.
News